|
|
|
|
| Protocol Number |
Indication |
Protocol |
NCT number |
| #SAT001 |
Advanced Solid Tumor |
A First- in- Human Phase 1 Trial to Determine the Safety and the Pharmackokinetic Profile of a Drug in Patients with Advanced Solid Tumors |
NCT03416816 |
| #SAT002 |
Advanced Solid Tumor |
A Phase 1 Study for Study Participants with BRAFF V-600 Mutation in Melanoma or other Solid Tumors |
NCT03864042 |
| #BRE001 |
Breast |
A Phase 1a/1b Study of an Anti-B7-H4 Antibody, in Patients with Advanced Solid Tumors |
NCT03514121 |
| BRE002 |
Breast |
A Phase 3 Open-Label, Randomized, Study of a Drug Versus Treatment of Physician’s Choice in Patients with Metastatic Breast Cancer who Have Stable Brain Metastases and Have Been Previously Treated |
NCT02915744 |
| BRE003 |
Breast |
A Phase 3, Randomized, Open-Label Trial to Compare the Efficacy and Safety of a Drug with Endocrine Therapy as Adjuvant Treatment in Patients with Hormone Receptor-Positive, HER2-Negative, Early Breast Cancer |
NCT03701334 |
| BRE004 |
Breast |
A multi-centre, double-blind, placebo-controlled, randomized phase II trial to compare efficacy of a drug in post-menopausal women with HR+ / HER2- metastatic breast cancer |
NCT03659136 |
| #END0001 |
Endometrial |
A Phase 1a/1b Study of an Antibody, in Patients with Advanced Solid Tumors |
NCT03514121 |
| #END0002 |
Endometrial |
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of a drug in Combination with Another Drug Versus Treatment of Physician’s Choice in Participants with Advanced Endometrial Cancer |
NCT03884101 |
| GAS001 |
Gastric |
A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating a Drug in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer |
NCT03694522 |
| LUN001 |
Lung NSCLC |
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy with or without a Drug EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) |
NCT03515837 |
| LYM001 |
Lymphoma |
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Drug in Patients with Relapsed Indolent B-Cell Non-Hodgkin’s Lymphoma (iNHL). |
NCT02367040 |
| MDS001 |
MDS Low Risk |
A Phase3,Open-Label,Randomized Study to Compare the Efficacy and Safety of a Drug Verses Standard Therapy for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk MDS in ESA Naïve Subjects who Require Red Blood Cell Transfusions |
NCT03682536 |
| MM001 |
Multiple Myeloma |
Multicenter Phase 2 Study injection in Combination with Standard Multiple Myeloma Treatment Regimens |
NCT03412565 |
| #OVA001 |
Ovarian |
A Phase 1a/1b Study of an Antibody, in Patients with Previously Treated Ovarian Cancer |
NCT03514121 |
| #OVA002 |
Ovarian |
A Randomized, Double-Blind, Phase 3 Study Comparison of Platinum-Based Therapy with Two Drugs Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III of IV Nonmucinous Epithelial Ovarian Cancer |
NCT03602859 |
| PRO001 |
Prostate |
A Phase 1b-2 Study of a Drug in Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer |
NCT03431350 |
| #SAT003 |
Solid Tumor |
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors |
NA |
